Pregled bibliografske jedinice broj: 1086971
Combined Albenazole- Praziquantel Treatment in Recurrent Brain Echinococcosis: Case Report
Combined Albenazole- Praziquantel Treatment in Recurrent Brain Echinococcosis: Case Report // Iranian Journal of Parasitology, 14 (2019), 3; 492-496 doi:10.18502/ijpa.v14i3.1492 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1086971 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Combined Albenazole- Praziquantel Treatment in
Recurrent Brain Echinococcosis: Case Report
Autori
Skuhala, Tomislava ; Trkulja, Vladimir ; Runje, Mislav ; Balen Topić, Mirjana ; Vukelić, Dalibor ; Desnica, Boško
Izvornik
Iranian Journal of Parasitology (1735-7020) 14
(2019), 3;
492-496
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Albendazole ; Albendazole-sulphoxide concentration ; Brain echinococcosis ; Praziquantel
Sažetak
We present a 40-year-old woman with a history of relapsing echinococcosis who had undergone a number of surgical procedures for cyst removal (right pulmectomy, cardiac surgery and 6 subsequent brain surgeries and two gamma knife procedures) and was admitted to University Hospital for Infectious Diseases "Fran Mihaljeviæ", Zagreb, Croatia in 2014 for pre- operative medical treatment of brain hydatidosis in the right parietal region. We aimed to attain a high cyst albendazole sulphoxide (ASO) concentration in order to achieve a more pronounced protoscolex inactivation and a high serum ASO concentration (reflecting the tissue concentrations) to reduce the risk of disease recurrence. The patient was treated with a higher dose of albendazole (15 mg/kg/day for 4 wk) that we had found effective in patients with liver hydatidosis, and combined with praziquantel over the last 14 d at a dose that is typically used to treat neurocysticercosis with an intention to improve ASO bioavailability. Neither serum nor cerebrospinal fluid concentrations on day 10 apparently differed from those on day 24 indicating a lack of an effect of praziquantel on ASO bioavailability. Intra-cystic ASO concentration was below the lower limit of quantification, but above the limit of detection. After the 7th episode of the disease and combined albendazole-praziquantel and surgery treatment, the patient achieved a 3-year remission. With the apparent lack of a meaningful pharmacokinetic praziquantel-albendazole interaction, this is most likely ascribable to the use of a higher albendazole dose than previously.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Stomatološki fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinika za infektivne bolesti "Dr Fran Mihaljević"
Profili:
Tomislava Skuhala
(autor)
Mislav Runje
(autor)
Dalibor Vukelić
(autor)
Mirjana Balen Topić
(autor)
Vladimir Trkulja
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus